Loading...
LVTX logo

LAVA Therapeutics N.V.NasdaqGS:LVTX Stock Report

Market Cap US$45.8m
Share Price
US$1.74
US$1.49
16.6% overvalued intrinsic discount
1Y12.3%
7D-2.2%
1D
Portfolio Value
​
View

LAVA Therapeutics N.V.

NasdaqGS:LVTX Stock Report

Market Cap: US$45.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

LAVA Therapeutics (LVTX) Stock Overview

Operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. More details

LVTX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Earnings have grown 2.7% per year over the past 5 years

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have meaningful revenue ($5M)

Does not have a meaningful market cap ($46M)


LVTX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

LAVA Therapeutics N.V. Competitors

Price History & Performance

Summary of share price highs, lows and changes for LAVA Therapeutics
Historical stock prices
Current Share PriceUS$1.74
52 Week HighUS$2.00
52 Week LowUS$0.85
Beta0.50
1 Month Change8.07%
3 Month Change12.26%
1 Year Change12.26%
3 Year Change-70.15%
5 Year Changen/a
Change since IPO-87.83%

Recent News & Updates

Analysis Article • Apr 06

Investors Aren't Buying LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Revenues

You may think that with a price-to-sales (or "P/S") ratio of 2.5x LAVA Therapeutics N.V. ( NASDAQ:LVTX ) is definitely...

Recent updates

Analysis Article • Apr 06

Investors Aren't Buying LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Revenues

You may think that with a price-to-sales (or "P/S") ratio of 2.5x LAVA Therapeutics N.V. ( NASDAQ:LVTX ) is definitely...
Analysis Article • Jun 02

Revenues Working Against LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Share Price Following 25% Dive

LAVA Therapeutics N.V. ( NASDAQ:LVTX ) shareholders that were waiting for something to happen have been dealt a blow...
Analysis Article • Mar 01

LAVA Therapeutics (NASDAQ:LVTX) Has Debt But No Earnings; Should You Worry?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Oct 18

LAVA Therapeutics: Assessing A Promising Innovator

Summary LAVA is able to form a highly profitable partnership with Seagen to develop LAVA-1223 for various solid tumors. The company's Gammabody platform holds strong promises as a delivery vehicle for a differentiated type of cellular therapy. There is an upcoming data release this November which indicates further upside to the stock. LAVA "Predicting rain doesn't count. Building arks does." - Warren Buffett I recently wrote a research article on Seagen (SGEN). That is to say, the company is entering into a partnership with LAVA Therapeutics (LVTX) for the use of its Precision Gammabody platform. As I was analyzing the aforesaid development, my intuition tells me that there has to be substantial unlocked value/growth in LAVA for Seagen to be interested in the firm. After all, a highly reputable firm would not form a partnership with a smaller operator unless there are tremendous promises. As I learned more about LAVA, I'm excited to deliver to you what I found. In this article, I'll present a fundamental analysis of LAVA and share with you my expectation of this growth equity. Figure 1: LAVA's chart (StockCharts) About The Company As usual, I'll feature a brief corporate overview for new investors. If you are familiar with the firm, I recommend that you skip to the next section. Operating out of the Netherlands and USA, LAVA is a clinical-stage company that is focused on the innovation and commercialization of cellular therapies. Leveraging the Gammabody platform, the company is advancing a portfolio of bispecific gamma delta T cell engagers to treat both solid and blood cancers. Figure 2: Therapeutics pipeline (LAVA) Partnerships On the partnership front, you can see that LAVA is able to ink two deals: one with Seagen and the other with Jansen which is a subsidiary of Johnson & Johnson (JNJ). That is big because it signifies that their drug/technology holds tremendous value. Else, big pharma wouldn't be interested in a partnership. Another point to consider is that the partner can offer their expertise as well as the capital needed for the lengthy and costly innovation process. As you know, both expertise and tremendous capital are required to develop blockbuster drugs. Mechanism of Action (i.e., MOA): Precision Gammabody Platform To Unlock Power of The Immune System Shifting gears, let us walk through the mechanism of action of the said platform. I know science can be quite boring for some of you. Nevertheless, it would make a huge difference in your investment returns in the long haul. That being said, if you've been following my research on cellular therapy, you can see that I'm a huge proponent of using the T-cells - the General of the body's natural defense (i.e., immune) system. Inside your body are constant battles between diseases and healing by the immune system. The two cells that are most important are the T-cells and B-cells. As you know, T-cells are "the Generals" while B-cells are "the commanding officers." By engineering the T-cells with the intelligence against various cancers, you can launch a highly efficacious attack to decimate these rogue cells. If you went back to my research on Kite Pharma (KITE) and Juno Therapeutics (JUNO), you can see that Kymriah saved lives in seemingly hopeless situations. From the figure below, you can tell that LAVA is using a subpopulation of Vγ9Vδ2 (Vgamma9 Vdelta2) T cells that has tremendous potential. For sake of simplicity, I will refer to those cells as GD-T-cells. Precisely speaking, these T-cells can communicate between both innate and adaptive immunity. The innate system is like your skin barrier against infection. Whereas, your adaptive immunity comes from the intelligence that T-cells gained from attacking invaders. When you focus on molecules that can integrate both innate and adaptive defenses together, the results are extremely powerful cancer eradication. Figure 3: GD-T-cells mechanisms of action (LAVA) Disease Context (i.e., DC): GD-T-cells Are Excellent At Eradicating Cancers Viewing the figure below, you can appreciate two trends. The first is that these GD-T-cells are present in many cancers. Second, the more of these GD-T-cells present, the better the patient's chances of survival. If you put those two facts together, you can see that GD-T-cells have tremendous therapeutic potential in the cancer disease context. As you can imagine, cancer cells exert immunosuppressive effects on their environment. Putting it another way, cancer cells excrete chemicals that dampen the immune response. Therefore, they put key immune cells like (B and T cells) to sleep. By activating the specialized GD-T-cells, those supreme Generals will wake up the body's whole defense army to launch an effective/efficient counterattack against cancers. In a nutshell, the GD-T-cell mechanism of action fits perfectly in the disease context of treating cancers like matching puzzle pieces. Figure 4: GD-T-cells as a differentiation factor against many cancers (LAVA) Supporting Data: Robust Early Results All the sound science with the matching MOA and Disease Context is meaningless unless GD-T-cells can demonstrate strong data results. In the preclinical models below, you can appreciate two developments. The first is the higher killing of cancer cells (i.e., cytotoxicity or lysis) comes from a higher concentration of GD-T-cells (i.e., Gammabody). The second is that longer treatment duration leads to more cancer cell destruction. Essentially, it indicates that GD-T-cells work against cancers. Figure 5: GD-T-cells exhibit potent cancer-killing in preclinical models (LAVA) A big concern about cancer drugs is that they can be quite toxic to normal cells. That's why patients on chemotherapy lose their hair, etc. Nevertheless, chemo/immunotherapies are still being used because their benefits outweigh the harms. Interestingly, GD-T-cells kill cancer cells (in both blood and solid tumor models) while not hitting the normal cells. As LAVA advances its drug, that selective killing is huge market differentiation. And that advantage would lead to launch success. Perhaps, that's why LAVA is able to garner partnership deals with Seagen and Janssen. Figure 6: Selective kill of cancer cells while sparing healthy counterparts (LAVA) The Seagen Deal As you know, Seagen put LAVA on the map by inking a huge partnership deal back on September 26. Accordingly, LAVA would receive $50M in upfront payment with the potential to earn up to $650M in milestones and royalties. Notably, the partnership would allow Seagen to in-license LAVA-1223 for EGFR-expressing solid tumors. Seagen also has an option to pick up two additional targets using the Gammabody platform. I noted in the prior article, Capturing the power of the Gammabody technology, LAVA-123 triggers a specific subset of T-cells ... to target a highly prevalent surface marker in solid tumors. Namely, that marker is the epidermal growth factor receptor (i.e., EGFR). You can think of LAVA-1223 as a smart medicine telling the GD T-cells to zone in on cancers having the EGFR on its surface while sparing normal cells. That confers tremendous specificity and highly efficacious cancer decimation. With EGFR being found on many cancer cells (colorectal, lung, head/neck), the potential of this first-in-class drug is tremendous. You can see that this deal is tremendous for LAVA. The $50M in cash is substantial capital for the $153.1M market cap company. LAVA doesn't have to do much work now. They can just simply wait for Seagen to use Gammabody to advance LAVA-1223 for various tumors. Meanwhile, the deal substantially improves LAVA's reputation in the market. Highly enthused by the collaboration, the president and CEO of LAVA (Stephen Hurly) commented,
Seeking Alpha • Sep 13

LAVA Therapeutics GAAP EPS of -$0.31 beats by $0.30, revenue of $0.47M beats by $0.11M

LAVA Therapeutics press release (NASDAQ:LVTX): Q2 GAAP EPS of -$0.31 beats by $0.30. Revenue of $0.47M (-56.5% Y/Y) beats by $0.11M. As of June 30, 2022, LAVA had cash, cash equivalents, and investments totaling $110.7 million compared to cash and cash equivalents of $133.2 million as of December 31, 2021, which we expect to be sufficient to fund the Company for approximately two years.

Shareholder Returns

LVTXUS BiotechsUS Market
7D-2.2%2.5%2.3%
1Y12.3%30.9%25.5%

Return vs Industry: LVTX underperformed the US Biotechs industry which returned 15.7% over the past year.

Return vs Market: LVTX exceeded the US Market which returned 9.9% over the past year.

Price Volatility

Is LVTX's price volatile compared to industry and market?
LVTX volatility
LVTX Average Weekly Movement5.2%
Biotechs Industry Average Movement10.5%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: LVTX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: LVTX's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201610Steve Hurlywww.lavatherapeutics.com

LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer.

LAVA Therapeutics N.V. Fundamentals Summary

How do LAVA Therapeutics's earnings and revenue compare to its market cap?
LVTX fundamental statistics
Market capUS$45.77m
Earnings (TTM)-US$23.18m
Revenue (TTM)US$4.99m
9.2x
P/S Ratio
-2.0x
P/E Ratio

Is LVTX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LVTX income statement (TTM)
RevenueUS$4.99m
Cost of RevenueUS$0
Gross ProfitUS$4.99m
Other ExpensesUS$28.17m
Earnings-US$23.18m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.88
Gross Margin100.00%
Net Profit Margin-464.59%
Debt/Equity Ratio0%

How did LVTX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/25 11:26
End of Day Share Price 2025/11/20 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

LAVA Therapeutics N.V. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Christopher HowertonJefferies LLC
Roger SongJefferies LLC
Jessica FyeJ.P. Morgan